Literature DB >> 3003635

Cervicovaginal peroxidases: markers of the fertile period.

J C Tsibris, S D Virgin, F S Khan-Dawood, P W Langenberg, J L Thomason, W N Spellacy.   

Abstract

The specific activity of guaiacol peroxidase was measured daily in human cervical mucus, vaginal fluids, and saliva during 45 cycles in 31 women. Also determined were basal body temperatures and serum hormones (luteinizing hormone [LH], estradiol, progesterone). The guaiacol peroxidase was extracted with 0.5 M CaCl2 and thus may be a different peroxidase from that obtained by noncalcium extraction procedures. The guaiacol peroxidase specific activity did not vary in the saliva during the cycle but fell sharply in the cervical mucus and vaginal fluid four to five days before the ovulation time, estimated by the LH peak, and rose again one to two days after ovulation. Anovulatory cycles did not show the midcycle drop in guaiacol peroxidase. Growth curve analysis gave excellent fitting of the guaiacol peroxidase data to a polynominal model. These data suggest that cervicovaginal guaiacol peroxidase may be clinically useful in detecting the fertile period for population control and for infertility treatment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3003635

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  3 in total

1.  Inactivation of human immunodeficiency virus type 1 by the amine oxidase-peroxidase system.

Authors:  S J Klebanoff; F Kazazi
Journal:  J Clin Microbiol       Date:  1995-08       Impact factor: 5.948

2.  Viricidal effect of polymorphonuclear leukocytes on human immunodeficiency virus-1. Role of the myeloperoxidase system.

Authors:  S J Klebanoff; R W Coombs
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

3.  Viricidal effect of Lactobacillus acidophilus on human immunodeficiency virus type 1: possible role in heterosexual transmission.

Authors:  S J Klebanoff; R W Coombs
Journal:  J Exp Med       Date:  1991-07-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.